Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation. by Matsuoka, Shuji et al.
Title
Establishment of a Therapeutic Anti-Pan HLA-Class II
Monoclonal Antibody That Directly Induces Lymphoma Cell
Death via Large Pore Formation.
Author(s)
Matsuoka, Shuji; Ishii, Yasuyuki; Nakao, Atsuhito; Abe,
Masaaki; Ohtsuji, Naomi; Momose, Shuji; Jin, Hui; Arase,
Hi ashi; Sugimoto, Koichi; Nakauchi, Yusuke; Masutani,
Hiroshi; Maeda, Michiyuki; Yagita, Hideo; Komatsu, Norio;
Hino, Okio




© 2016 Matsuoka et al. This is an open access article
distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the





Establishment of a Therapeutic Anti-Pan
HLA-Class II Monoclonal Antibody That
Directly Induces Lymphoma Cell Death via
Large Pore Formation
Shuji Matsuoka1*, Yasuyuki Ishii2, Atsuhito Nakao3, Masaaki Abe1, Naomi Ohtsuji1,
Shuji Momose1, Hui Jin4, Hisashi Arase4, Koichi Sugimoto5, Yusuke Nakauchi6,
Hiroshi Masutani7, Michiyuki Maeda7, Hideo Yagita8, Norio Komatsu9, Okio Hino1
1 Department of Pathology and Oncology, Juntendo University School of Medicine, Tokyo, 113–8421,
Japan, 2 RIKEN Research Center for Allergy and Immunology, Yokohama, 204–0022, Japan, 3 Department
of Immunology, Faculty of Medicine, Yamanashi University, Yamanashi, 409–3898, Japan, 4 Department of
Immunochemistry, WPI Immunology Frontier Research Center, Osaka University, Osaka, 565–0871, Japan,
5 Department of Hematology and Oncology, JR Tokyo Hospital, Tokyo, 151–8523, Japan, 6 Division of
Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science,
The University of Tokyo, Tokyo, 108–8639, Japan, 7 Department of Cell Biology, Institute for Virus
Research, Kyoto University, Kyoto, 606–8507, Japan, 8 Department of Immunology, Juntendo University
School of Medicine, Tokyo, 113–8421, Japan, 9 Division of Hematology, Department of Internal Medicine,
Juntendo University School of Medicine, Tokyo, 113–8421, Japan
*matsuoka@juntendo.ac.jp
Abstract
To develop a new therapeutic monoclonal Antibody (mAb) for Hodgkin lymphoma (HL), we
immunized a BALB/c mouse with live HL cell lines, alternating between two HL cell lines.
After hybridization, we screened the hybridoma clones by assessing direct cytotoxicity
against a HL cell line not used for immunization. We developed this strategy for establishing
mAb to reduce the risk of obtaining clonotypic mAb specific for single HL cell line. A newly
established mouse anti-human mAb (4713) triggered cytoskeleton-dependent, but comple-
ment- and caspase-independent, cell death in HL cell lines, Burkitt lymphoma cell lines, and
advanced adult T-cell leukemia cell lines. Intravenous injection of mAb 4713 in tumor-bear-
ing SCID mice improved survival significantly. mAb 4713 was revealed to be a mouse anti-
human pan-HLA class II mAb. Treatment with this mAb induced the formation of large pores
on the surface of target lymphoma cells within 30 min. This finding suggests that the cell
death process induced by this anti-pan HLA-class II mAb may involve the same death sig-
nals stimulated by a cytolytic anti-pan MHC class I mAb that also induces large pore forma-
tion. This multifaceted study supports the therapeutic potential of mAb 4713 for various
forms of lymphoma.
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Introduction
Monoclonal antibodies (mAbs) have dramatically improved the treatment of lymphoma. This
is particularly true for non-Hodgkin lymphoma (NHL), which can be treated with rituximab
(anti-CD20 mAb) [1,2]. However, rituximab only improves clinical outcome in combination
with chemotherapy, and a subset of the patients become rituximab-resistant after repetitive
treatments [3]. However, there is currently no mAb therapy available for Hodgkin’s disease.
Radiation therapy, chemotherapy, and combination therapy have been used to treat Hodgkin
lymphoma (HL) for many years with relatively good outcomes [4]. But these therapies are associ-
ated with the risks of sterility, secondary leukemia, and therapy-related myelodysplastic syn-
drome [5]. In addition, adult T-cell leukemia (ATL) is a very aggressive form of malignancy
caused by T-cell transformation induced by human T-lymphotropic virus type 1 (HTLV-1)
infection [6]. The prognosis of ATL is very poor, with a median survival time of only 24 months
despite the current therapies [7]. Irradiation and chemotherapy are not effective against ATL.
Therefore, there is an urgent need for new therapeutic agents addressing HL and ATL.
The principle behind our cytolytic anti-lymphoma mAb therapy is based on observations
made in animal studies. Unlike nude or SCID mice, normal strains of mice inoculated with live
malignant human cells survive and reject the inoculated cells [8]. During the first or second
challenge, the malignant cells are primarily killed by NK cells and CD8+ T cells, or ingested by
macrophages. However, during the course of repeated inoculations with malignant cells,
mouse lymphocytes generate antibodies against the malignant human cells. These antibodies
may constitute as major contributors to the rejection of malignant cells due to their efficacy in
killing target cells. This hypothesis served as the basis for experiments aimed at establishing
cytolytic anti-lymphoma mAbs.
Most therapeutic mAbs against cell surface molecules exert their effects mainly through
immunological mechanisms, including complement-dependent cytotoxicity (CDC) and anti-
body-dependent cellular cytotoxicity (ADCC). In addition to indirectly inducing Fc-dependent
cell death, several mAbs also directly induce programmed cell death [9–13]. Hybridoma clones
were selected based on the direct cytotoxicity of their supernatants to HL lymphoma cells. Dur-
ing the screening process, we ignored ADCC and CDC because they may be ineffective in lym-
phoma/leukemia patients immunocompromised by radiation, chemotherapy and the
malignant disease itself. Consequently, we identified an anti-pan HLA class II mAb with a
direct cytotoxic effect on lymphoma/leukemia cells, including HL, NHL, and advanced ATL
cells.
The aim of the present study was to investigate the cytotoxic activity of this newly estab-
lished anti-pan HLA class II mAb in several types of lymphoma/leukemia cell lines, both in
vitro and in vivo. We also compared the mechanism of cell death induced by this antibody and
the anti-pan MHC class I mAb we previously established [11–13]. The cell death induced by
anti-pan MHC class I and class II mAbs was cytoskeleton-dependent but caspase- and comple-
ment-independent. We demonstrate that cytolytic anti-MHC class I and II mAbs directly
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Mice and cells
The BALB/c and C.B-17/ICR-SCID mice [14] at 8 weeks of age were obtained from Japan SLC
Inc. (Hamamatsu, Japan) and CLEA Japan Inc. (Tokyo, Japan), respectively. All mice were
maintained under specific pathogen-free conditions. The Ethics Review Committee for Animal
Experimentation of Juntendo University Faculty of Medicine approved all animal experiments
(Project Number 727). Mice were euthanized using sodium pentobarbital, and appropriate
efforts were made to minimize suffering.
Human peripheral mononuclear cells were collected from healthy adult volunteers.
Informed, written consent was obtained from all study participants. The documents of partici-
pant consent are preserved in each participant’s medical records. Peripheral blood lymphocytes
were isolated from consenting healthy blood donors via centrifugation over Histopaque (Sigma
Chemical Co., St. Louis, MO). Human embryonic kidney 293T cells and human lymphoma
cell lines (L428, L540, KMH-2, Raji, Daudi, MOLT-4, C1R, HT, Jurkat, SU-DHL-1, K562,
NKL, NK-YS, and HANK-1) were purchased from the American Type Culture Collection
(Manassas, VA), the German Collection of Microorganisms and Cell Cultures/DSM (Braun-
schweig, Germany), or the Japan Cancer Research Resources Bank (Osaka, Japan). The HTLV-
1-infected IL-2-dependent cells (ATL-26c, ATL-72/2, and ED-40515) were established from
samples obtained from consenting ATL patients by cell culture in the presence of IL-2. The
HTLV-1-infected IL-2-independent cells (ATL-2, ATL-16, and ED40815) were established
from long-term cultures of IL-2-dependent cells. Each set of IL-2-dependent and IL-2-inde-
pendent cells had the same clonal origin, which was confirmed by examining the rearrange-
ment of T-cell receptor-γ gene and HTLV-1 proviral integration sites [15].
All lymphoma cells and ATL cell lines were cultured in RPMI 1640 or DMEMmedium con-
taining 10% heat-inactivated fetal calf serum (FCS) and antibiotics (100 U/ml penicillin and
100 μg/ml streptomycin) at 37°C, in the presence of 5% CO2. The IL-2-dependent HTLV-
1-infected T cells and NK lymphoma cell lines were maintained by adding IL-2 (7.5 ng/ml;
PeproTech EC; London, UK) to the culture medium.
Transfectants
The 293T cell line was transiently transfected with pME18S expression plasmid containing
HLA-DP, HLA-DQ, or HLA-DR cDNA and pMx-GFP expression plasmid using polyethyleni-
mine (Polysciences; Tokyo, Japan). Two days after transfection, their expression of HLA-DP or
HLA-DR on the transfectants was confirmed by FACS using HLA-DP/HLA-DR mAb HL-40
(EXBIO; Tokyo, Japan) or HLA-DQ-specific mAb HLA-DQ1 (BioLegend; Tokyo, Japan).
Reagents and antibodies
Latrunculin B was purchased from Biomol Research Labs (PA, USA). Z-VAD-FMK and
Z-Asp-DCB were purchased from the Peptide Institute Inc. (Osaka, Japan), and cathepsin
inhibitor III (Z-FG-HNO-BzOME) from Calbiochem (Tokyo, Japan). IM-54 was purchased
from Santa Cruz Biotechnology (UK). Necrostatin-1 was purchased from Enzo Biochem Inc.
(NY). EDTA, forskolin, cytochalasin D, 4,5-dihydroxy-1, 3-benzenedisulfonic acid (Tiron),
Alexa 488-conjugated rat anti-mouse Ig, and mouse IgG were purchased from Sigma-Aldrich.
Anti-asialo GM1 was purchased fromWako Pure Chemical Industries (Osaka, Japan). Anti-
Fas mAb was purchased fromMBL (Nagoya, Japan). Gout anti-rabbit IgG (H+L) antibody
Alexa 488 conjugate was purchased from Thermo Fisher Science (MA).
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Establishment of mAb 4713
A BALB/c mouse was immunized intraperitoneally every 2 weeks for 3 months with live HL
cells. The injections were alternated between L428 and KM-H2 cells to establish mAbs reactive
to common molecules on the surface of HL cell lines. Three days after the last immunization,
mouse spleen cells were fused with P3U1-nonproducing myeloma cells using the polyethylene
glycol method, and the resulting hybridomas were selected using hypoxanthine–aminopterin–
thymidine (HAT) culture medium (Corning Cellgro; VA, USA). Hybridomas producing anti-
bodies showing direct cytolytic activity against a 3rd HL cell line, L540, were selected based on
the trypan blue dye exclusion test. This immunizing and screening method was adopted to
establish mAbs with direct cytotoxic effects on multiple lymphoma cell lines, and to prevent
the establishment of mAbs clonotypically reactive to a single cell line. We identified one mAb
(4713) that consistently killed HL cell lines directly.
Flow cytometry analysis and cytotoxicity assay
The molecular targets of mAb 4713 were analyzed by incubating cells with mouse mAb 4713,
followed by Alexa 488-conjugated rat anti-mouse IgG on ice, and then subjecting the cells to
flow cytometry analysis using a BD LSRFortessa cell analyzer (BD Biosciences).
The cytotoxic activity of mAb 4713 was assessed by incubating a mixture of target cells
(2 × 106 cells/ml) in RPMI medium containing 2% decomplemented (56°C, 30 min) FCS and
the mAb (3 μg/ml) at 37°C for 2 h (unless stated otherwise). The percentage of lysed cells was
determined in triplicate based on trypan blue dye exclusion or PI staining, followed by FACS
on the BD LSRFortessa cell analyzer. As the results obtained through PI staining were nearly
identical to those obtained by trypan blue dye exclusion, only the dye exclusion results are
presented.
Potential inhibitors of mAb 4713 cytotoxicity were added to the cell cultures either 1 h
before (z-VAD-FMK, z-Asp-DCB, LY294002, cytochalasin D, and latrunculin B) or 2 h before
(wortmannin) the addition of mAb 4713. Sodium azide, EDTA, and cytochalasin D were
added to the assay medium during the cytolytic assay to test the effects of these reagents. The
concentration of each reagent was optimized during preliminary experiments based on meth-
ods described previously [11, 12, 16].
Tumor xenograft experiments
Five C.B-17/ICR-SCID mice were injected intraperitoneally with rabbit anti-asialo GM1
(Wako Pure Chemicals) to deplete the NK cells. After 24 h, they received an intravenous injec-
tion of Raji cells (5 × 106) suspended in 200 μl of PBS. Five days, or 5 and 12 days, after inocula-
tion of Raji cells, the mice were injected intravenously with mAb 4713 (1 μg/mouse).
Affinity chromatography
Purified mAb 4713 (5 mg) was immobilized using HiTrap NHS-activated HP (1 mL; GE
Healthcare Inc.), according to the manufacturer’s protocol. A total of 1 × 108 cells were incu-
bated (5 min; 4°C) in PBS (pH 7) containing 1% (w/w) Nonidet P-40 (Wako Chemical, Japan)
and a protease inhibitor cocktail (Roche, Inc.). After centrifugation, the supernatant was recov-
ered and applied on the 4713 mAb-HiTrap. After washing the column with 5 volumes of lysis
buffer, the bound proteins were eluted with 0.1% (w/w) glycine–HCl (pH 2.7), and neutralized
with 1 M Tris-HCl (pH 9.0).
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Western blot analysis
Protein samples were separated by SDS-PAGE and transferred to a PVDF membrane. After
treatment with Pierce Fast Blocking Buffer (Pierce Biotechnology Inc., Tokyo, Japan), the
membrane was incubated with buffer containing mAb 4713 (1 μg/mL), followed by a horserad-
ish peroxidase-conjugated secondary antibody. The membrane was treated with enhanced
chemiluminescent (ECL) reagent (Amersham; Tokyo, Japan), and the reactive protein bands
were visualized with a Fujifilm image analyzer.
Scanning electron microscopy
Samples of L428 cells were incubated with mAb 4713 (37°C; 15 or 30 min), and then washed
and resuspended in PBS containing 2% FCS. The cell suspension was fixed by adding 0.1 vol-
ume of 1% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.3), and incubating the samples at
4°C for 2 h. The fixed cells were washed with 0.1 M cacodylate buffer, post-fixed in 1% OsO4 (1
h; 4°C), dehydrated in approximately 50%–100% ethanol, substituted with t-butyl alcohol,
dried at −10°C under a vacuum, and observed with a high resolution scanning electron micro-
scope (S-900; Hitachi LTD, Tokyo).
Statistical analysis
All experiments were conducted in triplicate, and the data were expressed as mean ± SD. The
resulting mean values were<10% SD. Statistical analyses were performed using SPSS 14.0 soft-
ware (IBM, NY). The data sets were compared by Student’s t tests, and P values<0.05 were
considered significant.
Results
The cytotoxic activity of mAb 4713 against multiple types of lymphoma
cells
One cloned mAb, named mAb 4713 induced rapid cell death in HD lymphoma cell line, L428,
dose-dependently (S2 Fig). The cytolytic activity of mAb 4713 was also tested against various
types of lymphoma cells, including HL and NHL cell lines. The cells were incubated with mAb
4713 at 37°C for 2 h (Table 1 upper column). The treatment induced rapid cell lysis in several
cell lines. All of the tested HL cell lines showed varying degrees of mortality. Approximately
30% to 90% of the cells were killed within 2 h. Non-HL cells, including Burkitt lymphoma cells,
were also killed by mAb 4713. The observed cytotoxicity was independent of serum comple-
ments because heating ascitic fluid (56°C; 30 min) did not affect the cytotoxicity (unpublished
data), and cell death occurred even under serum-free culture conditions. The sensitivity of lym-
phoma cell lines to mAb 4713-induced cell death and cell-surface binding of mAb 4713 were
confirmed by flow cytometry. Dead cells were stained with propidium iodide (PI) (Fig 1A).
Whereas mAb 4713 stained NK lymphoma cell lines, they were not sensitive to mAb
4713-induced cell death (Table 1 upper column). Even the NK lymphoma cell line (NKL) with
a high expression level of the target molecules was not susceptible to mAb 4713-induced cell
death (Fig 1A). Thus, there was no correlation between the expression level of target molecule
and the cell death sensitivity.
The cytotoxic activity of 4713 against ATL cell lines
We tested the cytolytic activity of mAb 4713 against ATL cell lines, which were classified as
either non-advanced (IL-2-dependent) or advanced (IL-2-independent) types (15). None of
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the IL-2-dependent ATL cells tested were killed by mAb 4713. In contrast, all of the IL-2-inde-
pendent ATL cell lines tested were sensitive to 4713 killing. A total of 50% to 70% of the IL-
2-independent ATL cells were killed by 4713 within 2 h (Table 1 lower column and Fig 1B).
Similar results were obtained for IL-2-dependent ATL cell lines cultured without IL-2 and for
IL-2-independent ATL cell lines cultured with IL-2 (unpublished data), indicating that exoge-
nous IL-2 has no direct effect on mAb 4713-induced cell death in ATL cells. As mAb 4713 was
not cytotoxic to NK lymphoma cell lines that depend on supplemental IL-2 for culture mainte-
nance, we conclude that mAb 4713 has cytolytic activity only for lymphoma/leukemia cells
that proliferate without exogenous IL-2.
Normal peripheral blood lymphocytes collected from healthy donors also reacted with mAb
4713, but they were not sensitive to mAb 4713-induced killing, even after Concanavalin (Con) A-
or lipopolysaccharide (LPS)-mediated activation (Fig 2). Therefore, mAb 4713 does not damage
non-cancerous lymphocytes. Despite its broad spectrum of binding activity, the cytotoxic activity
of mAb 4713 was limited to IL-2-independent lymphoma cell lines (Table 1, Figs 1 and 2).
The anti-tumor activity of mAb 4713 in a tumor-bearing mouse model
The potential therapeutic effect of mAb 4713 against lymphoma was tested in vivo using the
human tumor xenograft SCID mouse model. To deplete NK cells, the mice were pretreated
with anti-asialo-GM1 antisera 1 day before Raji Burkitt lymphoma cells were xenografted.
Thereafter, mAb 4713 or control mouse IgG was injected intravenously on day 5, or on day 5 and
Table 1. Cytotoxic effects of mAb4713 on lymphoma/leukemia cell lines.
Cell line Cell type Reactivity % killing Comment
Cytotoxic effects on various lymphoma cell lines
L428 Hodgkin lymphoma positive 92 ±2 HLA-DR(+) CD20(+)
L540 Hodgkin lymphoma positive 40 ±3 HLA-DR(+) CD15(+)
KM-H2 Hodgkin lymphoma positive 32 ±4 HLA-DR(+) CD58(+)
RAJI Burkitt lymphoma positive 58 ±2 HLA-DR(+) CD25(+)
Daudi Burkitt lymphoma positive 56 ±3 MHC class I-deﬁcient
C1R B cell lymphoma positive 65 ±3 MHC class I-deﬁcient
HT B lymphoblast positive 68 ±2 Diffuse mixed lymphoma
Jurkat T cell lymphoma negative 0 ±0 HLA-DR(−) Fas(+)
MOLT-4 ALL (T cell) negative 0 ±2 HLA-DR(−) CD4(+)
SU-DHL-1 diffuse large negative 0 ±0 HLA-DR(−) CD25(+)
K562 myelogenous negative 0 ±3 HLA-DR(−) CD25(+)
NKL NK lymphoma positive 0 ±1 HLA-DR(+) IL-2-dependent
NKYS NK lymphoma positive 0 ±2 HLA-DR(+) IL-2-dependent
HANK-1 NK lymphoma positive 0 ±0 HLA-DR(+) IL-2-dependent
Cytotoxic effects on ATL cell lines
ATL-26c ATL positive 0 ±3 IL-2-dependent
ATL-72/2 ATL positive 0 ±3 IL-2-dependent
ED-40515 ATL positive 0 ±3 IL-2-dependent
ATL-55T ATL positive 52±6 IL-2-independent
ATL-2 ATL positive 73±3 IL-2-independent
ED-40810 ATL positive 69±4 IL-2-independent
The reactivity of mAb 4713 was determined by FACS analysis as described in Fig 1.
Lymphoma and ATL cells (2 × 106 cells/ml) were incubated with mAb 4713 (3 μg/ml) for 2 h at 37°C. The percentages of dead cells (% killing) were
determined based on trypan blue dye exclusion and are indicated as means±SD of triplicated samples.
doi:10.1371/journal.pone.0150496.t001
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12, after injection of the Raji cells. Fig 1C shows that mAb 4713 significantly improved survival,
compared with the control IgG-treated mice. On day 70 after treatment, 60% of the mice treated
with two doses of mAb 4713 were still alive, whereas all those treated with a single dose were dead
(Fig 1C). These data demonstrate that mAb 4713 causes a dose-dependent increase in survival in
mice bearing Raji Burkitt's lymphoma xenografts. Although we tried to inoculate HD cells to SCID
mouse intensely, any dose of HD cells tested could not be engrafted to SCIDmice successfully.
Therefore we could not demonstrate the therapeutic effect of mAb 4713 on HD cells in vivo.
The molecular targets of mAb 4713
The molecular targets of mAb 4713 were identified by affinity chromatography using column-
bound mAb 4713. Lysates of mAb 4713-sensitive L428 HL cells [17] were applied to the col-
umn, and the eluate was recovered with glycine–HCl buffer. Fig 3A shows that mAb 4713
Fig 1. Reactivity and cytotoxic activity of mAb 4713 against lymphoma cell lines. (A) Flow cytometry
analysis of mAb 4713 reactivity analyzed by incubating different lymphoma cell lines with mAb 4713 (4°C; 2
h), followed by Alexa 488-conjugated rat anti-mouse Igs (green histogram). Cytotoxicity was analyzed based
on propidium iodide (PI) staining of dead cells (red histogram). (B) Cytotoxic effects of mAb 4713 on IL-
2-dependent or IL-2-independent ATL cell lines analyzed by PI staining after incubation with mAb 4713
(37°C; 1 or 2 h). Similar data were obtained in two independent experiments. (C) Kaplan–Meier survival
analysis of mAb 4713-treated C.B-17/ICR-SCID mice bearing Raji lymphoma xenografts. The Raji-injected
SCID mice (n = 5) were treated with mAb 4713 once (red line) or twice (brown line), or with control IgG once
(green line). **p = 0.01 versus isotype control.
doi:10.1371/journal.pone.0150496.g001
Fig 2. Lack of cytotoxicity of mAb 4713 on lymphocytes from healthy donors. Freshly isolated, or
Concanavalin (Con) A- or LPS-activated (12 h), peripheral blood lymphocytes were incubated with mAb 4713
for 2 h, then with Alexa 488-conjugated anti-mouse IgG (green) or propidium iodide (red). Negative controls
are shown by black lines.
doi:10.1371/journal.pone.0150496.g002
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bound to two major proteins of 28 kDa and 32 kDa. They were identified as the HLA-DR α-
chain and β -chain by peptide mass fingerprinting analysis. Western blot analysis using mAb
4713 detected only the 28-kDa protein (Fig 3B). Collectively, these data suggest that the molec-
ular target of mAb 4713 is the HLA-DR β-chain. Accordingly, the HLA class II-positive cell
lines were reactive to mAb 4713, whereas many of the HLA class II-negative cell lines were not
(Table 1, S1 Fig). High HLA class II expression has been reported on ATL cells [18]. Therefore,
we tested whether mAb 4713 recognizes other MHC class II antigens, namely HLA-DP,
HLA-DQ and HLA-DR. We prepared HLA-DP, HLA-DQ, or HLA-DR transfectants, and ana-
lyzed their reactivity with mAb 4713. Flow cytometry indicated that mAb 4713 stained all of
the HLA class II-transfected cells, but not the control cells transfected with green fluorescent
protein (GFP) alone (Fig 3C). Together, these data suggest that mAb 4713 recognizes an epi-
tope common to all HLA class II β-chains. However, the transfectants were not sensitive to
mAb 4713-induced killing. Therefore, the cell surface expression of HLA class II molecules on
target cells is essential, but not sufficient, for mAb 4713-induced cell death.
The mAb 4713-induced cell death signaling pathway
The underlying mechanism of mAb 4713-induced cell death was investigated by testing the
effects of several potential inhibitors on the cytotoxic activity of mAb 4713 against L428 HL
cell line and Raji Burkitt lymphoma cell line. The caspase inhibitors, z-VAD-FMK [19] and z-
Asp-DCB [20], and the PI-3 kinase inhibitors, wortmannin [21] and LY294002 [22], did not
inhibit the cytotoxic activity of mAb 4713 (Fig 3A). To confirm the difference between mAb
4713 induced cell death from apoptosis, we performed several experiments. Western blot anal-
ysis supported the caspase-independent cell death mechanism. Treatment of Jurkat cells with
cytochrome C showed bands of cleaved caspase-3, but treatment of L428 cells with mAb 4713
did not (S3A Fig). Similarly cleaved caspase-3 was not detected in L428 cells treated with mAb
4713 by flow cytometric analysis (S3B Fig). Furthermore, depolarization of mitochondrial
membrane was not observed during mAb 4713-induced cell death (S4 Fig). The necroptosis
inhibitor, Necrostatin-1 [23], and the necrosis inhibitor, IM-54 [24], also failed to inhibit the
cytotoxic activity of mAb 4713 (Fig 4A). Consequently, mAb 4713-induced cell death is not
apoptosis, necroptosis, nor necrosis. In contrast, both cytochalasin D, which depolymerizes
cytoskeletal actin filaments to actin monomers [25], and latrunculin B, which reduces the
monomeric actin pool available for polymerization [26], completely inhibited mAb
4713-induced cell death (Fig 4A). These data are reminiscent of previous findings regarding
the cytolytic activity of anti-pan MHC class I mAb against lymphocytes [11, 12]. Therefore,
cytolytic anti- pan MHC class I and class II antibodies may use the shared signaling events to
induce cell death. We hypothesized that cell death was initiated by a disorganization of cyto-
skeletal actin filament systems induced by intensive cross-linking between anti-pan MHC
mAbs and abundant cell surface MHC molecules because it was reported that Fab fragments of
anti-pan MHCmAbs have no cytolytic activity, whereas cross-linking of Fab with anti-mouse
Igs reconstituted cytotoxicity in T cells ([11] and our unpublished data].
Type II anti-CD20 mAbs and some anti-HLA-DR mAbs have been reported to induce non-
apoptotic cell death in lymphoma and leukemia cells through a reactive oxygen species (ROS)-
dependent pathway [16]. The extent of mAb-induced cell death correlated with the generation
Fig 3. Reactivity of mAb 4713 with HLA class II molecules. (A) Purification of mAb 4713-binding proteins
from L428 cell lysate by affinity chromatography using mAb 4713. (B) Western blot analysis of the affinity-
purified proteins isolated from RAW264.7 or L427 cell lysate using mAb 4713. (C) Flow cytometry analysis of
mAb 4713 reactivity with HLA-DP-, HLA-DQ-, or HLA-DR-transfected 293T cells. Cells were incubated with
mAb 4713, followed by PE-conjugated rat anti-mouse Igs.
doi:10.1371/journal.pone.0150496.g003
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of ROS mediated by NADPH oxidase. In the case of type II anti-CD20 mAbs, cell death
involved lysosomal membrane permeabilization and subsequent release of lysosomal cathep-
sins into the cytosol to trigger ROS production. In the present study, a cell-permeable ROS
scavenger 4,5-dihydroxy-1, 3-benzenedisulfonic acid (Tiron) had no effect on the mAb
4713-induced cell death, suggesting a ROS-independent mechanism (Fig 4A). As a matter of
fact, ROS production was not observed after exposure to mAb 4713 (S5 Fig). These results sug-
gest that mAb 4713 induces cell death ROS-independently.
In addition, cathepsin inhibitor III was reported to prevent type II anti-CD20 mAb-induced
cytotoxicity in Raji cells [16]. We observed a cell type-dependent response of mAb
4713-induced cell death to cathepsin inhibitor III (Fig 4A). This compound reduced the killing
of Raji Burkitt lymphoma cells by 30%, but had no effect on the survival of L428 HL cells.
These results suggest that lysosomal cathepsins constitute non-essential participants in the
mAb 4713-induced killing.
Several type II anti-CD20 mAbs and an anti-HLA-DR mAb were recently reported to
induce caspase and complement-independent non-apoptotic cell death [16, 27]. Therefore,
these type II anti-CD20 mAbs may use a similar cell death signals to our anti-pan HLA-class II
mAb. However, at least some of the death signals associated with these mAbs are different. For
example, type II anti-CD20 mAb-mediated cell death was associated with the induction of
homotypic intercellular adhesion [16]. Furthermore, actin redistribution toward cell-to-cell
contact area was both critical for cell aggregation and subsequent cell death stimulated by type
II anti-CD20 mAb or anti-HLA-DR mAbs [27]. In the present study, limiting dilution experi-
ments were conducted to test whether aggregation and homotypic adhesion are required for
the mAb 4713-induced cell death. Target L428 HL cells were seeded (0.3 cells/well; 96 wells)
with 3 μg/ml mAb 4713 or control mouse IgG. After 2 h, most wells contained a single live cell,
namely 30 wells with IgG and 3 wells with mAb 4713 (Fig 4B). These data show that a single
target cell was killed by mAb 4713 in the absence of homotypic adhesion or aggregation.
Light and electron microscopy findings
The mechanism of mAb 4713-induced cell death was visualized using different microscopy
approaches. First, light microscopic examination confirmed the occurrence of single cell death,
in the absence of aggregation, after a 30-min incubation of L428 HL cells with mAb 4713 (Fig
5A). Second, scanning electron microscopy revealed the formation of giant pores at the surface
of L428 HL target cells during the early phase of mAb 4713-induced killing (Fig 5B). The giant
pores (approximately 3 μm) appeared as early as 15–30 min after the addition of mAb 4713 to
the culture medium. This finding is distinct from those observed during apoptotic or necrotic
cell death.
Discussion
We designed an immunizing and screening method to establish a mAb reactive to common
molecules on the surface of HL cell lines. This method identified an anti-pan HLA class II mAb
(mAb 4713) with direct cytotoxic effect on HL, NHL, and advanced ATL cells, but inactive on
Fig 4. Mechanism of mAb 4713-induced cell death involving the cytoskeleton. (A) Impact of chemical inhibitors on the cytotoxic activity of mAb 4713
against L428 and Raji cells. The inhibitors were added 1 or 2 h before the cytotoxicity assay. The percentage of dead cells was determined by trypan blue dye
exclusion. **p = 0.01 versus none. ***p = 0.001 versus none. The agents were caspase inhibitors (z-VAD-FMK and z-Asp-DCB), PI-3 kinase inhibitors
(wortmannin and LY294002), cytoskeletal inhibitors (cytochalasin D and latrunculin B), necroptosis inhibitor (Necrostatin-1), necrosis inhibitor (IM-54), a
cathepsin inhibitor (Cath inib III), and reactive oxygen species scavenger (Tiron). (B) Limiting dilution experiments in which L428 cells were seeded (0.3 cells/
well; 96 wells) with 3 μg/ml mAb 4713 or control IgG. After 2 h, the number of live cells per well was counted. **p = 0.01 versus isotype control. ***p = 0.001
versus control IgG. Each value represents the mean ± SD.
doi:10.1371/journal.pone.0150496.g004
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Fig 5. Microscopy analysis of mAb 4713-induced single cell death shows giant pores. (A) Light
microscopy image showing that the incubation of L428 cells with mAb 4713 caused rapid aggregation and
death of single cells after 30 min, as shown by trypan blue exclusion staining. , single cell death; Δ,
aggregation of cells. Bar: 50 μm (B) Scanning electron microscopy image showing the formation of giant
pores on L428 Hodgkin lymphoma cells after a 15 or 30 min incubation with mAb 4713.
doi:10.1371/journal.pone.0150496.g005
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peripheral blood lymphocytes from healthy donors. The therapeutic potential of anti-pan HLA
class II mAb 4713 was clearly demonstrated in vivo in the human tumor xenograft SCID
mouse model, even after single treatment. Therefore, this mAb presents tremendous therapeu-
tic potentials for a variety of leukemias/lymphomas.
Some mAbs against MHC class I and class II molecules were shown to induce apoptotic or
non-apoptotic cell death in lymphoma cells and activated lymphocytes [11–13, 28–31]. Their
ligation to cell surface MHCmolecules rapidly and directly induces complement- and caspase-
independent cell death. Whereas MHC class I molecules are abundantly expressed on almost
all somatic cells, MHC class II molecules are confined to various antigen-presenting cells of the
immune system (B cells, activated T cells, macrophages, and dendritic cells). It is noteworthy
that non-cancerous and resting lymphocytes are resistant to the cytolytic effects of mAbs tar-
geting MHCmolecules. Thus, cell death induced by anti-MHCmAbs is selective for lymphoma
cells and activated lymphocytes.
Mouse anti-pan HLA class II mAb 4713 directly induced non-apoptotic cell death in lym-
phoma cells. Giant pores were detected at the surface of the target cells within 30 min of mAb
4713 exposure. We previously reported the formation of similar giant pores on mouse T cells
treated with rat anti-mouse MHC class I mAb RE2 (S6 Fig)[11]. This antibody recognized all
strains of mice, except MHC class I-deficient mice. Furthermore, mAb RE2 prevented the
binding of anti-H-2Kk and anti-H-2Dk mAbs to the surface of H-2k haplotype cells. These data
showed that mAb RE2 recognizes pan-MHC class I molecules. We also demonstrated that
mAb RE2 induces direct cell death by cytoskeleton-dependent, but caspase- and complement-
independent, mechanisms [11, 12], as in the case of mAb 4713. In fact, cell death induced by
anti-pan HLA class II mAb 4713 and anti-pan MHC class I mAb RE2 shares similar chemical
sensitivity profiles. In both cases, cytoskeletal inhibitors (cytochalasin D and latrunculin B)
reduced cell killing by>90%, whereas caspase inhibitors (Z-VAD-fmk and Z-Asp-DCB) and
PI-3 kinase inhibitors (wortmannin and LY294002) had no effect [12]. Collectively, these data
suggest that the antibody-mediated ligation of MHC class I or MHC class II molecules may
induce cell death in lymphoma cells through common signaling machineries. We named the
cell death induced by cytolytic anti-pan MHC antibodies as anapocosis. Anapoco means holes
in Japanese.
The anti-CD20 mAb rituximab shows improved clinical outcomes in patients with non-
Hodgkin lymphoma when used in combination with chemotherapy. Moreover, an anti-CC
chemokine receptor 4 (CCR4) mAb has been developed as a novel therapeutic agent for ATL
patients [32,33]. However, a substantial proportion of patients remain to suffer from relapses
and acquire resistance to these mAb therapies. In addition, some patients with lymphoma/leu-
kemia are immunocompromised. Therefore, the ability of the anti-pan HLA class II mAb 4713
to induce complement- and ADCC-independent cell death may present a clinical advantage
over conventional therapeutic mAbs for leukemia/lymphoma.
Supporting Information
S1 Fig. Expression of HLA-DR on various cell lines. Various cell lines indicate in Table 1
were stained with anti-HLA-DR mAb (clone:LN3) (Biolegend CA) and analyzed by flow
cytometry as described in Materials and Methods. Green lines show staining profiles of
HLA-DR.
(TIFF)
S2 Fig. Kinetics and dose dependency of mAb 4713 cytotoxicity. A. Kinetics of cytotoxic
effect of mAb 4713 on L428. B. Dose-dependent cytotoxic effect of mAb 4713 on L428. Tar-
get cells (L428) were resuspended at 106/ml in RPMI supplemented with 2%FCS. mAb was
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added at 3 μg/ml (A) or the indicated concentrations (B) for the indicated periods (A) or 120
min (B). The percentage of alive cells and %cytotoxicity were determined by dye exclusion test
triplicate.
(TIFF)
S3 Fig. Caspase-3-independent cytotoxicity of mAb 4713. A. Western blotting analysis.
Activation (cleavage) of caspase-3 was detected in positive control Jurkat cells treated with
cytochrome C, but not L428 cells treated with mAb 4713. We performed this experiment using
Apoptosis Marker: Cleaved Caspase-3 (Asp175) Western Detection kit (Cell Signaling Tech-
nology, MA). B. Flow cytometric analysis. After treatment with anti-Fas mAb or mAb 4713,
target cells (Jurkat and L428) were stained with cleaved caspase-3 (Asp175)-specific antibody
(Cell Signaling) and analyzed by flow cytometry.
(TIFF)
S4 Fig. Mitochondrial membrane depolarization was not induced by mAb 4713. L428 cells
were incubated with 1 μg/ml anti-Fas mAb for 8h, 3 μg/ml mAb 4713 for 30 min, or 50M
CCCP for 5h, followed by staining with Mito Probe JC-1 (Abcam). JC-1 red fluorescence was
analyzed by flow cytometry.
(TIFF)
S5 Fig. Cellular Reactive Oxygen Species (ROS) was not produced by mAb 4713-induced
cell death. L428 cells were labeled with 20μM 2’, 7’-dichlorofluorescin diacetate (DCFDA) and
incubated with 3μg/ml of mAb 4713 for 30 min or 0.5M of tert-butyl hydrogen peroxide
(TBHP9 for 5h, then analyzed by flow cytometry. ROS was not produced by incubation with
mAb 4713.
(TIFF)
S6 Fig. Scanning Microscopy findings.MAb RE2 (anti-mouse pan MHC class I mAb)-
induced giant pore on the surface of target T cell within 5 min. To prepare the cells for observa-
tion with a scanning electron microscope, MS-S2 cells were incubated with RE2 mAb (anti-pan
MHC class I mAb) at 37°C for 5 min and then washed with and resuspended in PBS containing
2% FCS. The suspension was fixed with 10 vol of 1% glutaraldehyde in 0.1 M cacodylate buffer
(pH 7.3) at 4°C for 2h. Fixed cells were mounted on electric conductive double sided tape (Nis-
shin EM, Tokyo, Japan) coated with gold-palladium coating system (Polaron, England), and
they were examined by a scanning electron scope (model S-430; Hitachi Ltd., Tokyo, Japan).
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